.png)
Agenzia Italiana del Farmaco
Direct communication with healthcare professionals on GAVRETO (pralsetinib) - Direct communication with healthcare professionals on GAVRETO (pralsetinib)
Direct communication with healthcare professionals on GAVRETO (pralsetinib)
Direct communication with healthcare professionals.
Tuberculosis, mostly extrapulmonary, has been reported in patients receiving pralsetinib.
Before starting treatment, patients should be evaluated for active and inactive (“latent”) tuberculosis, as per local recommendations.
In patients with active or latent tuberculosis, standard antimycobacterial therapy should be initiated before treatment with Gavreto is started.
Published on: 16 June 2023
